Emovo Care

Emovo Care operates at the intersection of assistive technology, medical devices, robotics, neuroscience, and digital health. Its stated focus is narrower than that of broad rehabilitation-equipment companies: it is developing accessible robotic devices intended to bring movement support into the home, beginning with hand function for people with motor impairments. Emovo Grasp differentiates through a portable form factor, artificial-tendon mechanics, and an emphasis on enabling users to grasp and release objects outside clinical settings. The company also combines robotics, human-machine interfaces, usability, and clinical engineering, with research roots at EPFL and collaboration with the BioRob laboratory. Compared with larger medical-device manufacturers, Emovo Care appears to have a much smaller team and earlier commercial scale, but its specialization may support focused development for hemiparetic stroke patients and other users with impaired hand movement. Its Swiss trial program provides an early path for user feedback and clinical engagement.

Emovo Care’s trajectory reflects a research-led medical-device company progressing from academic technology toward home-based rehabilitation. The company was founded in 2020, following core technology development during an EPFL PhD, and received a $153,728 pre-seed investment from Venture Kick on May 6, 2020. A further seed round involving Next Humanity Ventures was announced on Oct 8, 2021, although its amount is undisclosed. Financing accelerated with the $537,203 SICTIC-led seed round on Jun 18, 2024, followed by a $111,637 Biopôle-led seed round on Nov 6, 2025. These financings brought total disclosed funding to $802,568 and indicate continued capital formation after the initial research phase. Product development has centered on Emovo Grasp, a portable hand orthosis using artificial tendons, alongside free trials for eligible Swiss candidates. The company’s current hiring of M.Sc. thesis students and interns through EPFL BioRob suggests it is still building technical and clinical capacity rather than operating at large commercial scale.